Inquiry Basket
| Catalog | Product Name | CAS Number |
|---|---|---|
| BADC-00364 | Fmoc-Val-Cit-PAB | 159858-22-7 |
| Fmoc-Val-Cit-PAB is a cathepsin B-cleavable linker precursor used in ADCs for controlled drug release. It incorporates a peptide spacer for enhanced intracellular cleavage. | Inquiry | |
| BADC-00366 | N-SMP | 55750-61-3 |
| N-SMP is a potent synthetic compound known for its efficacy against various neurological disorders. As a powerful inhibitor, this compound specifically targets key enzymes involved in the progression of these debilitating diseases. In addition, N-SMP is also widely used as a linker for antibody-drug conjugation. | Inquiry | |
| BADC-00369 | Fmoc-Val-Cit-PAB-PNP | 863971-53-3 |
| Fmoc-Val-Cit-PAB-PNP is a cathepsin B-sensitive linker used in ADC synthesis. With a cleavable Val-Cit dipeptide and PNP activation, it enables selective payload release inside tumor cells. Suitable for advanced ADC development requiring precision and tumor-selective release. | Inquiry | |
| BADC-00372 | SPDP | 68181-17-9 |
| SPDP is a heterobifunctional ADC crosslinker featuring NHS ester and cleavable disulfide bonds. Used in antibody-drug conjugates for thiol-reactive bioconjugation, it supports controlled drug release under reductive conditions. Ideal for constructing cleavable linkers in targeted delivery systems. | Inquiry | |
| BADC-00373 | 2,5-dioxopyrrolidin-1-yl 4-methyl-4-(pyridin-2-yldisulfanyl)pentanoate | 890409-85-5 |
| 2,5-dioxopyrrolidin-1-yl 4-methyl-4-(pyridin-2-yldisulfanyl)pentanoate serves as a cleavable ADC linker that facilitates disulfide bond formation between antibodies and payloads, ensuring controlled intracellular drug release and enhanced ADC potency in targeted cancer therapies. | Inquiry | |
| BADC-00374 | m-C-tri(CH2-PEG1-NHS ester) | 173414-89-6 |
| m-C-tri(CH2-PEG1-NHS ester) signifies a multifaceted and utilitarian agent extensively employed within the realm of biomedicine. Its profound versatility lies in its adeptness as a reactive entity, facilitating the intricate conjugation of pharmaceuticals or biomolecular entities to meticulously designated targets. | Inquiry | |
| BADC-00382 | Bis-PEG1-NHS ester | 65869-64-9 |
| Bis-PEG1-NHS ester is a symmetric bifunctional PEG linker with two NHS groups for protein crosslinking. Supports flexible conjugation in ADC and biopharma applications. | Inquiry | |
| BADC-00405 | NHS-PEG4-azide | 944251-24-5 |
| NHS-PEG4-azide is a bifunctional linker featuring azide and NHS groups for amine coupling and click chemistry. Widely used in ADC and bioconjugate synthesis. | Inquiry | |
| BADC-00409 | Azido-PEG2-NHS ester | 1312309-64-0 |
| Azido-PEG2-NHS ester is a non-cleavable 2-unit PEG linker that can be used to synthesize antibody-conjugated drugs (ADCs). | Inquiry | |
| BADC-00410 | 6-Azidohexanoic acid NHS ester | 866363-70-4 |
| 6-Azidohexanoic acid NHS ester is an azide-functionalized linker for click chemistry applications in ADCs. Enables efficient amide bond formation and bioorthogonal conjugation. | Inquiry | |
| BADC-00415 | BCN-PEG4-NHS ester | 1702356-19-1 |
| BCN-PEG4-NHS ester is a click chemistry-enabled linker for strain-promoted azide-alkyne cycloaddition (SPAAC). Ideal for bioconjugation in ADCs without copper catalysis. | Inquiry | |
| BADC-00453 | Mal-PEG2-NHS ester | 1433997-01-3 |
| Mal-PEG2-NHS ester is a non-cleavable ADC linker containing the Maleimide group, 2-unit PEG, and NHS ester. | Inquiry | |
| BADC-00466 | 2,5-dioxopyrrolidin-1-yl 4-methyl-4-((5-nitropyridin-2-yl)disulfanyl)pentanoate | 663598-98-9 |
| NO2-SPDMV is a biomedical product used in the drug development of various diseases. With its unique chemical structure, it exhibits potential therapeutic properties to target specific receptors and enzymes involved in the progression of certain disorders. Its applications include drug research to treat cardiovascular disease, neurological diseases, and inflammatory diseases, among others. | Inquiry | |
| BADC-00477 | 1-(2,5-dioxopyrrolidin-1-yloxy)-1-oxo-4-(pyridin-2-yldisulfanyl)butane-2-sulfonic acid | 1193111-39-5 |
| 1-(2,5-dioxopyrrolidin-1-yloxy)-1-oxo-4-(pyridin-2-yldisulfanyl)butane-2-sulfonic acid is an ADC linker featuring reactive NHS ester and pyridyl disulfide groups for efficient conjugation and reversible linkage, optimizing antibody-drug conjugate stability and payload release. | Inquiry | |
| BADC-00498 | Propargyl-NHS Ester | 1174157-65-3 |
| Propargyl-NHS ester is an indispensable small molecule tool in the biomedical field and is a key coupling agent that promotes bioconjugation reactions. This compound labels a range of biomolecules including proteins and peptides, facilitating their unambiguous identification and meticulous monitoring. With its sheer versatility, Propargyl-NHS Ester coordinates a range of tasks, including drug delivery systems, diagnostics and targeted therapies. | Inquiry | |
| BADC-00501 | Mc-Val-Cit-PABC-PNP | 159857-81-5 |
| Mc-Val-Cit-PABC-PNP is a cleavable ADC linker designed for targeted drug release in tumor microenvironments. Featuring a para-aminobenzyl carbamate (PABC) spacer and PNP leaving group, this valine-citrulline linker is ideal for protease-sensitive antibody-drug conjugates, enabling efficient payload delivery in lysosomal conditions. | Inquiry | |
| BADC-00510 | (S)-di-tert-butyl 2-(3-((S)-6-amino-1-tert-butoxy-1-oxohexan-2-yl)ureido)pentanedioate | 1025796-31-9 |
| (S)-Di-tert-butyl 2-(3-((S)-6-amino-1-tert-butoxy-1-oxohexan-2-yl)ureido)pentanedioate is a PEG linker for antibody-drug-conjugation (ADC). | Inquiry | |
| BADC-00511 | DUPA(OtBu)-OH | 1026987-94-9 |
| DUPA(OtBu)-OH is a PEG linker for antibody-drug-conjugation (ADC). DUPA(OtBu)-OH is a DUPA precursor. DUPA is used as the targeting moiety to actively deliver Docetaxel (DTX) for treatment of Prostate-Specific Membrane Antigen (PSMA) expressing prostate cancer. | Inquiry | |
| BADC-00610 | Mc-Val-Cit-PAB-Cl | 1639351-92-0 |
| Mc-Val-Cit-PAB-Cl is a maleimide cleavable ADC linker with valine-citrulline peptide and PAB spacer for enzymatic drug release. Designed for stable antibody conjugation and targeted cancer therapy applications. | Inquiry | |
| BADC-00615 | JUN68744 | 1703768-74-4 |
| JUN68744 is a useful peptide linker for synthesis of PSMA-617 (vipivotide tetraxetan), which is a ligand used to make 177Lu-PSMA-617, a radioactive molecule to fight cancer. PSMA-617 originally was developed at the German Cancer Research Center and the Heidelberg University Hospital. ABX held the exclusive license to bring the treatment, which targets prostate-specific membrane antigen (PSMA), through early clinical development. | Inquiry |
